Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rotavirus vaccine-PATH-malaria
- Development stage
- Unknown
- Lead developer
- Bharat Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
The designation **rotavirus vaccine-PATH-malaria** refers to the live-attenuated oral rotavirus vaccine (specifically the pentavalent formulation known as **ROTASIIL** or the monovalent **ROTAVAC**) as utilized in clinical trials sponsored by **PATH** to evaluate its co-administration and scheduling with malaria vaccines, such as **R21/Matrix-M**. Developed through partnerships between PATH and Indian manufacturers (Serum Institute of India for ROTASIIL and Bharat Biotech for ROTAVAC), these vaccines are designed to prevent severe gastroenteritis caused by rotavirus infection in infants. In the context of malaria research, studies like the R21/Matrix-M Schedule Optimization trial (NCT05483972) assess the safety and immunogenicity of giving these rotavirus vaccines alongside malaria candidates to ensure that the immune response to the malaria vaccine does not interfere with the protective efficacy of standard childhood immunizations.
- Brand names
- ROTASIILROTAVAC
- Other names
- Rotavirus, Live Attenuated (Oral) VaccinePentavalent Rotavirus VaccineORV 116EORV116EORV-116E
02
Targets
RVA (Rotavirus A)
Beyond the preview
Go deeper on rotavirus vaccine-PATH-malaria.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rotavirus vaccine-PATH-malaria.